BridgeBio Q2 net loss $157.9M; acoramidis Phase 3 ATTR-CM meets primary endpoint, NDA planned by end 2023

BridgeBio Pharma, Inc.

2023-Q2 EPS reported -$1.90 revenue$3,467,000

Phase 3 ATTRibute-CM of acoramids achieved highly significant primary endpoint, Win Ratio 1.8 (p<0.0001); NDA filing planned by end 2023.
Revenue $1.6M in Q2 vs $73.7M prior year due to $70.2M one-time license in 2022; net loss $157.9M.
Cash & equivalents $353.2M; mgmt expects $300-350M to support acoramidis launch.
Announced positive infigratinib Phase 2 results in achondroplasia; mean AHV +3.38 cm/year.
BBP-418 Phase 3 FORTIFY trial dosed first patient; FDA discussion supports accelerated approval potential.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BridgeBio Pharma, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, BridgeBio Pharma, Inc. reported recent business updates and its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-037590

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.